via Penn Medicine
In a mouse study, researchers used nanotechnology and previous knowledge of a protein pathway to significantly reduce knee cartilage degeneration and pain
There is currently no cure for osteoarthritis, but a group of scientists believe they’ve discovered a method through which a simple knee injection could potentially stop the disease’s effects. These researchers showed that they could target a specific protein pathway in mice, put it into overdrive and halt cartilage degeneration over time. Building on that finding, they were able to show that treating mice with surgery-induced knee cartilage degeneration through the same pathway via the state of the art of nanomedicine could dramatically reduce the cartilage degeneration and knee pain. These findings were published in Science Translational Medicine.
“Our lab is one of the few in the world studying epidermal growth factor receptor (EGFR) signaling in cartilage and, from the beginning, we have found that EGFR deficiency or inactivation accelerates osteoarthritis progression in mice,” said Ling Qin, PhD, an associate professor of Orthopaedic Surgery. “Thus, we proposed that its activation could be used to treat osteoarthritis, and in this study, we’ve proven for the first time that over-activating it inside the knee blocks the progression of osteoarthritis.”
Qin explained that tests from the other labs that do work with EGFR have drawn “confusing and controversial” results. But Qin’s lab has consistently found the ties between osteoarthritis and EGFR deficiencies, which formed the bedrock of their hypothesis.
The researchers compared typical mice with those that had a molecule that bound to EGFR, called a ligand, that was over-overexpressed in chondrocytes, the building blocks of cartilage. This overexpression drives the over-activation of EGFR signaling in knee cartilage. When examining them, the mice with overexpressed HBEGF (the EGFR ligand) were found to consistently have enlarged cartilage, meaning that it wasn’t wearing away like the mice who had normal EGFR activity. Moreover, when these mice aged to adulthood, their cartilage was resistant to degeneration and other hallmarks of osteoarthritis, even if their knee’s meniscus was damaged.
To further prove that the over-activated EGFR was the reason for the mice’s resiliency, the researchers found that gefitinib treatments, which are designed to block EFGR function, took away the protection against cartilage degeneration.
With all of this knowledge gained, the researchers turned an eye toward potential clinical treatment solutions. In a new series of tests they created nanotherapeutics by attaching a potent EGFR ligand, transforming growth factor-alpha, onto synthetic nanoparticles, to inject into mice who already had cartilage damage in their knees.
“Free EGFR ligands have a short half-life and cannot be retained inside of a joint capsule due to their small size,” explained Zhiliang Cheng, PhD, a research associate professor in Penn Engineering and another of the co-corresponding authors on the paper. “Nanoparticles help to protect them from degradation, restrict them within the joint, reduce off-target toxicity, and carry them deep inside dense cartilage to reach chondrocytes.”
When mice were injected with these nanotherapeutics, the researchers saw that they slowed cartilage degeneration and bone hardening, as well as eased knee pain. There also were no major side effects seen in the mice who were treated.
“While many of the technical aspects of this application still need to be worked out, the ability to stop or slow the course of osteoarthritis with an injection rather than surgery would dramatically change how we feel and function as we age and after injury,” said one of the study’s co- authors, Jaimo Ahn, MD, PhD, a former faculty member at Penn Medicine now chief of orthopaedic trauma and associate chair of orthopaedic surgery at the University of Michigan.
The treatment is likely some time away for human patients, but the nanoparticles used have already been clinically tested and deemed safe, which makes it easier to quickly translate to clinical use.
“There is a great unmet medical need for a disease-modifying osteoarthritis drug,” Qin said. “In the future, we will optimize the drug design and test it in large animals before proceeding to clinical trials. We hope our research could lead to a novel drug that will improve the health and well-being of the more than 27 million osteoarthritis patients in the United States.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Reduced serum levels of anti-Mullerian hormone is a putative biomarker of early knee osteoarthritis in middle-aged females at menopausal transitionon March 2, 2021 at 5:11 am
A recent epidemiological study revealed that the highest prevalence of early knee osteoarthritis (OA) was observed in females aged ≥ 50 years. The major causal factor of early knee OA was sex. Despite ...
- Telephone CBT-I Shown to Improve Sleep, Fatigue in Older Adults With Osteoarthritis Painon February 26, 2021 at 10:54 am
Patients with osteoarthritis-related pain were shown to benefit from cognitive behavioral therapy for insomnia (CBT-I) via telephone, in which the treatment significantly improved sleep and fatigue ...
- A molecular quantitative trait locus map for osteoarthritison February 26, 2021 at 9:16 am
Understanding the molecular effects of disease variants in relevant tissues is essential to understanding and treating disease. Here, the authors discover expression and protein quantitative trait ...
- Study shows opioid use among US patients with knee osteoarthritis costs 14 billion dollars in societal costson February 24, 2021 at 11:50 pm
Although guidelines do not recommend use of opioids to manage pain for individuals with knee osteoarthritis, a recent study published early online in Arthritis Care & Research, an official journal of ...
- Research shows the effectiveness of a digital healthcare treatment for osteoarthritison February 24, 2021 at 4:12 pm
The steadily increasing prevalence and high costs of treating chronic joint pain worldwide poses a challenge for healthcare systems and healthcare payers.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Delivering Nanomedicine to Solid Tumorson February 27, 2021 at 4:00 pm
In conclusion, the dense and heterogeneous structure of the extracellular matrix in desmoplastic tumors blocks large nanotherapeutics and results in the heterogeneous distribution of these agents.
- Review Highlights Potential of Nanotherapies in Diagnosing, Treating Rare CNS Diseaseson February 26, 2021 at 7:03 am
The resulting disorders can take the shape of rare CNS-related diseases. However, “the number of studies dedicated to treating these rare diseases using nanotherapeutics is limited, which is mostly ...
- Why is Gainesville Florida’s Biotech Hub?on February 25, 2021 at 4:00 pm
Nanotherapeutics was Florida born and bred. Their initial technology originated from the University of Florida and the company moved into the SMCI. The company grew by first acquiring small commercial ...
- Delivering Nanomedicine to Solid Tumorson February 25, 2021 at 4:00 pm
These barriers are likely to be responsible for the modest survival benefit offered by many FDA-approved nanotherapeutics and must be overcome for the promise of nanomedicine in patients to be ...
- Micro Chemotherapy Market Research Revealing the Growth Rate and Business Opportunities to 2027on February 23, 2021 at 11:49 am
Market Research Engine has published a new report titled as "Micro Chemotherapy Market Size By Product (Physical ...